These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23080362)

  • 1. Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis?
    Qayyum F; Holbrook A; Lam J; Kovacs MJ; Schulman S
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):705-13. PubMed ID: 23080362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006650. PubMed ID: 18425959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Labedi N; Barba M; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Jun; (6):CD006650. PubMed ID: 21678361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
    Louzada ML; Majeed H; Wells PS
    Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
    Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
    Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients.
    Laporte S; Bertoletti L; Romera A; Mismetti P; Pérez de Llano LA; Meyer G
    Thromb Res; 2012 Dec; 130(6):853-8. PubMed ID: 22939430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials.
    Di Minno MN; Lupoli R; Di Minno A; Ambrosino P; Scalera A; Dentali F
    Ann Med; 2015 Feb; 47(1):61-8. PubMed ID: 25665582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
    Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
    Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
    Wang W; Su Y; Wu C; Sun Y; Dai N; Chen W; Zhang J; Xu Y; Brindis RG; Xu D; Li J
    BMC Cardiovasc Disord; 2020 Feb; 20(1):53. PubMed ID: 32013892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guideline update. VTE disease: which agents, and when.
    Holten KB; Merok J
    J Fam Pract; 2009 Mar; 58(3):E1. PubMed ID: 19284934
    [No Abstract]   [Full Text] [Related]  

  • 15. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
    Mai V; Bertoletti L; Cucherat M; Jardel S; Grange C; Provencher S; Lega JC
    PLoS One; 2019; 14(4):e0214134. PubMed ID: 30933993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review.
    Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
    J Exp Clin Cancer Res; 2008 Jul; 27(1):21. PubMed ID: 18634550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled analysis of randomized controlled trials.
    Brown GA
    J Arthroplasty; 2009 Sep; 24(6 Suppl):77-83. PubMed ID: 19628366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention and treatment of venous thromboembolism in patients with cancer].
    Struve S; Wendtner CM
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2007-9. PubMed ID: 22987155
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cancer, thromboembolia and antithrombotic therapy: is there an anticoagulant of choice?].
    Scharf RE
    Dtsch Med Wochenschr; 2011 Nov; 136(47):2403. PubMed ID: 22094968
    [No Abstract]   [Full Text] [Related]  

  • 20. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes.
    Vardi M; Laor A; Bitterman H
    Thromb Haemost; 2009 Nov; 102(5):879-86. PubMed ID: 19888523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.